Tg Therapeutics (TGTX) Short-term Investments (2014 - 2026)

Tg Therapeutics' Short-term Investments history runs 13 years deep, the most recent figure standing at $72.2 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 49.88% year-over-year to $72.2 million in Q1 2026; TTM through Mar 2026 was $72.2 million, a 49.88% decrease from a year earlier, with the FY2025 full-year figure at $62.8 million, down 52.08% from the prior year.
• Short-term Investments grew to $72.2 million in Q1 2026 per TGTX's latest filing, from $62.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $145.2 million in Q3 2024 and bottomed at $47.5 million in Q1 2022.
• The 5-year median for Short-term Investments is $78.2 million (2023), against an average of $91.5 million.
• Across the five-year window, Short-term Investments soared 273.99% in 2022 and tumbled 60.4% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $59.4 million in 2022, then soared by 109.81% to $124.6 million in 2023, then rose by 5.24% to $131.1 million in 2024, then plunged by 52.08% to $62.8 million in 2025, then climbed by 14.96% to $72.2 million in 2026.
• Per Business Quant, the three latest TGTX Short-term Investments figures stand at $72.2 million (Q1 2026), $62.8 million (Q4 2025), and $57.5 million (Q3 2025).